Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
South Africa's national health reform : how leading R&D pharmaceutical companies are responding
Mini Dissertation (MBA)--University of Pretoria, 2017.
Saved in:
| Other Authors: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
University of Pretoria
2017
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613446643646464 |
|---|---|
| access_status_str | Open Access |
| author2 | Cajee, Zaheeda |
| author_browse | Cajee, Zaheeda |
| author_facet | Cajee, Zaheeda |
| collection | Thesis |
| dc_rights_str_mv | © 2017 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. |
| description | Mini Dissertation (MBA)--University of Pretoria, 2017. |
| format | Thesis |
| id | oai:repository.up.ac.za:2263/59838 |
| institution | University of Pretoria (South Africa) |
| language | English |
| last_indexed | 2026-06-10T12:36:17.013Z |
| license_str | Other — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository |
| publishDate | 2017 |
| publishDateRange | 2017 |
| publishDateSort | 2017 |
| publisher | University of Pretoria |
| publisherStr | University of Pretoria |
| record_format | dspace |
| source_str | UPSpace — University of Pretoria Institutional Repository |
| spelling | oai:repository.up.ac.za:2263/59838 South Africa's national health reform : how leading R&D pharmaceutical companies are responding Cajee, Zaheeda ichelp@gibs.co.za Bezuidenhout, Charmaine UCTD Mini Dissertation (MBA)--University of Pretoria, 2017. In December 2015, the South African government released the much anticipated White paper on the planned National Health Insurance (NHI) (Department of Health, 2015) raising more questions ("NHI White Paper", 2016) amongst stakeholders. Frost and Sullivan (2011) have suggested that the planned cost containment of the NHI will benefit generic companies whilst research and development (R&D) companies, the biggest upstream providers in the private healthcare sector in South Africa, might consider pulling out of the country. In order to ensure long-term sustainable growth within the new NHI landscape, R&D pharmaceutical companies will have to align their strategic approach to meet several stakeholder demands in this changing environment. Therefore, this study's primary objective was to investigate the behavioural tactics of R&D pharmaceutical companies in response to the NHI, viewed from their perspectives as the change recipients. An in-depth exploratory qualitative research design was employed as the researcher was concerned not only with how these pharmaceutical companies are preparing for the NHI, but also with the rationale underpinning those selected change tactics employed by R&D pharmaceutical companies. A total of five, highly experienced senior executives, representing leading R&D pharmaceutical companies, were interviewed. Findings from this research revealed several important themes, from the need for diversified pharmaceutical portfolios in order to address the country's disease burden, to improved market access and public-private partnerships to overcome current challenges. However, throughout this research project, the importance of extensive stakeholder engagement, particularly from the government, was identified as both a barrier and enabler to the successful implementation of the NHI. ms2017 Gordon Institute of Business Science (GIBS) MBA Unrestricted 2017-04-07T13:05:59Z 2017-04-07T13:05:59Z 2017-03-30 2017 Mini Dissertation Bezuidenhout, C 2017, South Africa's national health reform : how leading R&D pharmaceutical companies are responding, MBA Mini Dissertation, University of Pretoria, Pretoria, viewed yymmdd <http://hdl.handle.net/2263/59838> http://hdl.handle.net/2263/59838 en © 2017 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. application/pdf University of Pretoria |
| spellingShingle | UCTD South Africa's national health reform : how leading R&D pharmaceutical companies are responding |
| title | South Africa's national health reform : how leading R&D pharmaceutical companies are responding |
| title_full | South Africa's national health reform : how leading R&D pharmaceutical companies are responding |
| title_fullStr | South Africa's national health reform : how leading R&D pharmaceutical companies are responding |
| title_full_unstemmed | South Africa's national health reform : how leading R&D pharmaceutical companies are responding |
| title_short | South Africa's national health reform : how leading R&D pharmaceutical companies are responding |
| title_sort | south africa s national health reform how leading r d pharmaceutical companies are responding |
| topic | UCTD |
| url | http://hdl.handle.net/2263/59838 |